Jun 07, 2023 / 07:00PM GMT
Mike Yee - Jefferies & Co., Inc. - Analyst
Welcome to another great afternoon session here at the Jefferies Healthcare Conference. I'm pleased to have with us the CEO of Olema Pharmaceuticals, Sean Bohen, up here with us. Sean, Olema is developing an oral CERAN. If you'd like to get a little more tactical, we'll get into that.
Questions and Answers:
Mike Yee - Jefferies & Co., Inc. - AnalystBut importantly, there's been a lot of developments data recently and upcoming data later this year. So let's talk a little bit about, just from a high level, first is introduction. What -- where are we with OP-1250 today? What do we know about this molecule today?
What do we know about it recently with some recent data that's presented? And what do you think the street is not appreciating about this molecule you have for breast cancer?
Sean Bohen - Olema Pharmaceuticals, Inc. - President, CEO & Director
Yes, great. Well, with two hours, we'll be sure to be able to cover all of that. Yeah, no.
Trustpilot
